Clinical Trial Update: Efficacy, PK, Immunogenicity and Safety of Wilate in Severe Von Willebrand Disease (VWD) Patients <6 Years of Age [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update evaluating the efficacy, pharmacokinetics, immunogenicity, and safety of Wilate in severe Von Willebrand Disease in patients under…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Von Willebrand Disease

Drugs mentioned

• Wilate (von Willebrand factor/factor VIII concentrate)

Snippet

Sponsor: Octapharma | Conditions: Von Willebrand Disease | Phase 3 | Status: COMPLETED | Results posted: 2026-02-20